Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03305874 · ClinicalTrials.gov registry record
Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 5
- Enrollment target
NCT03305874 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 5 participants.
The verdict
NCT03305874 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
Contrast agent is typically used during routine cardiac intervention in order to enhance the imaging necessary to perform the procedure. Using this contrast agent could lead to kidney injury, called contrast induced nephropathy (CIN). Currently, the methods used to reduce the risk of CIN include reducing the amount of contrast agent used and using a hydration strategy during procedure. A computer-based risk tool has been developed which reports a risk score for the likelihood a person undergoing cardiac intervention gets CIN and a proposed corresponding hydration strategy to reduce the risk of CIN. The purpose of this study is to determine whether the rate of CIN decreases when the treating physician has access to this risk tool during the procedure.
Interventions
- OTHER Exposure to CBCIN risk score
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2023-07-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03305874
The ClinicalTrials.gov registry entry for NCT03305874 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exposure to CBCIN risk score is the first listed.
NCT03305874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03305874 about?
NCT03305874 is a clinical study titled "Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization". Contrast agent is typically used during routine cardiac intervention in order to enhance the imaging necessary to perform the procedure. Using this contrast agent could lead to kidney injury, called contrast induced nephropathy (CIN). Currently, the methods used to reduce the risk of CIN include red...
What is the current status of trial NCT03305874?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2018-03-07. Estimated completion is 2023-07-17.
What interventions are being tested in trial NCT03305874?
The interventions under investigation include: Exposure to CBCIN risk score (OTHER).
Who is sponsoring clinical trial NCT03305874?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.